同步放化疗对晚期宫颈癌患者肿瘤标志物及血清TK1、HE4、VEGF的影响  

Influence of concurrent chemoradiotherapy on tumor markers and serum TK1,HE4,VEGF in patients with advanced cervical cancer

作　　者：汤巍巍[1] 于明新[1] 尉阳[2] 程召霞 

机构地区：[1]辽宁省肿瘤医院妇科,辽宁沈阳110042 [2]中国医科大学盛京医院妇产科,辽宁沈阳110004 [3]沈阳市妇婴医院妇产科,辽宁沈阳110011

出　　处：《海南医学院学报》2014年第4期534-536,540,共4页Journal of Hainan Medical University

基　　金：辽宁省自然科学基金(c2617823)~~

摘　　要：目的:分析研究同步放化疗对晚期宫颈癌患者肿瘤标志物及血清胸苷激酶1(TK1)、人附睾分泌蛋白4(HE4)、血管内皮生长因子(VEGF)的影响。方法:选取本院收治的78例晚期宫颈癌患者为研究对象,将其随机分为对照组(常规放疗组)39例和观察组(同步放化疗组)39例,然后将两组治疗有效率及治疗前后的血清肿瘤标志物及血清TK1、HE4、VEGF水平进行比较。结果:观察组的治疗有效率明显高于对照组,治疗后1个周期及3个周期时的血清肿瘤标志物及血清TK1、HE4、VEGF水平均明显低于对照组,差异具有统计学意义(P<0.05)。结论:同步放化疗在晚期宫颈癌患者中的应用效果较好,且对于肿瘤标志物及血清TK1、HE4、VEGF也有一定影响,因此更适用于此类患者。Objective.. To analyze and study the influence of concurrent chemoradiotherapy for the tumor markers and serum TK1, HE4,VEGF in patients with advanced cervical cancer. Methods. A total of 78 patients with advanced cervical cancer were selected as research object,and they were randomly divided into control group（routine radiotherapy group, n=39 cases）and observation group（concurrent cbemora diotherapy group, n=39 cases） ,then the treatment effective rates and serum tumor markers,TK1, HE4, VEGF levels before and at＇ter the treatment of two groups were analyzed and compared. Results：The treat ment effective rates of observation group were obviously higher than those of control group,serum tumormarkers, TK1, HE4, VEGF at 1 cycle and 3 cycles after the treatment were all obviously lower than those of control group （P0.05）. Oonclusion..The effect of concurrent chemoradiotherapy in patients with ad- vanced cervical cancer is better, and its influence for the tumor markers and serum TK1, HE4, VEGF of pa- tients is more active too, so it is more suitable for these patients .

关 键 词：同步放化疗 晚期宫颈癌 肿瘤标志物 胸苷激酶1 人附睾分泌蛋白4 血管内皮生长因子 

分 类 号：R737.33[医药卫生—肿瘤]